Sol S.p.a. MIL:SOL

SOL GROUP: consolidated sales for the first quarter of 2026.

Published

Source: MarketScreener

PRESS RELEASE

The Board of Directors has reviewed the consolidated sales for the first quarter of 2026, confirming the SOL Group's steady and sustained growth.

  • Consolidated Net Sales: € 465.2 million

    (+7.2% compared to € 433.9 million as of 31/03/2025)

  • Net Sales Division "Technical Gases": € 219.8 million

    (+3.1% compared to € 213.2 million as of 31/03/2025)

  • Net Sales Division "Home Care": € 245.4 million

(+11.2% compared to € 220.7 million as of 31/03/2025) Monza, May 12, 2026 - The Board of Directors of SOL S.p.A., the holding company of a multinational Group listed on the Italian Stock Exchange with over 7,700 employees, active in the technical and medical gases sector as well as home care, examined today the sales performance of the SOL Group for the period from January to March 2026.

The first quarter of 2026 was characterized by a progressive stabilization of the global economy. However, this occurred within a framework of "variable speed" growth across different geographic areas and significant pressure on energy costs due to ongoing conflicts, particularly in the Middle East.

Revenue Analysis

In this complex economic environment, consolidated turnover reached € 465.2 million, representing a 7.2% increase over the previous year. This result includes a -0.7 percentage point impact from exchange rate fluctuations and a +1.5 percentage point contribution from changes in the scope of consolidation. Growth was driven by both the domestic (€175.4 million, +5.3% vs. Q1 2025) and international markets (€289.8 million, +8.4% vs. Q1 2025).

Performance by Division
  • Technical Gases Division achieved € 219.8 million (+3.1% vs. Q1 2025)in sales. This result highlights the Group's ability to acquire new customers within its target markets despite stagnant industrial production and high volatility in energy costs.
  • Home Care Division (Vivisol) confirmed its strong growth momentum with sales of
€245.4 million (+11.2% vs. Q1 2025). This performance was driven by a constant increase in prescriptions for new patients, particularly in the sleep apnea and advanced nursing care segments. Partnerships and Acquisitions

During the first three months of 2026, the SOL Group continued its expansion through two key extraordinary transactions:

  1. The acquisition of 100% of the Italian company Haemopharm Biofluids S.r.l. to develop the production of peritoneal dialysis fluids.

  2. The acquisition of 100% of VitalAire Schweiz AG, a leading provider of home respiratory care in Switzerland.

Management Commentary

"The results of the first three months of 2026 confirm the SOL Group's agility in adapting to changes in the economic environment" stated Marco Annoni, Vice-President of SOL S.p.A. "We have demonstrated a strong capacity to react to the industrial production that is still in a consolidation phase and the resilience of the services sector, all within the framework of our strategy of diversification and internationalization".

"We look to the coming months with determination and confidence, backed by an operational solidity that allows us to confirm our growth targets. We remain vigilant and reactive to the uncertainties of the global geopolitical situation and the marked volatility of energy markets, while standing ready to enter new strategic partnerships" - concluded Aldo Fumagalli Romario, President of SOL S.p.A.

********************

The Manager responsible for preparing the corporate financial reports of SOL S.p.A., Marco Michele Leccese, declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance (Legislative Decree 58/1998), that the accounting information contained in this press release fairly represents to the documentary results, books, and accounting records.

SOL is an Italian multinational Group operating in Europe, Turkey, Morocco, Brazil, India, China, Kuwait, Ecuador, and Peru in two distinct main sectors: the production, applied research, and marketing of technical, pure, and medical gases (Technical Gases Division) and Home Care (Home Care Division).

Monza, May 12, 2026